“This transaction will ensure that we have a secure clinical supply of ” said Dr. Zhi Hong, Chairman and CEO of Brii Biopharma. “As BRII enters latestage clinical development, this transaction will also retain more potential returns from BRII within Brii Biopharma, bringing more value to shareholders.”
Currently, Fosun Pharma has initiated multiple combination therapy studies involving BRII to achieve higher functional cure rates for patients with chronic hepatitis B HBV infection. Existing studies continue to demonstrate thailand phone number list the potential of BRII to screen HBV patients with a high response to curative therapy. Based on previously accumulated and latest data, a large, prospective, confirmatory Phase b study ENRICH study evaluating BRII sequentially combined with elebsiran and PEGIFNα has completed patient recruitment.
About Hepatitis B
Hepatitis B virus HBV infection is one of the world's most significant infectious disease threats, infecting more than million people worldwide. Chronic HBV infection is the leading cause of liver disease, and approximately , people die each year from complications of chronic HBV infection. The number of people with chronic HBV infection in China has reached million, which is of great concern.